Lonza : More Sensitive Non-endotoxin Pyrogen Detection Now Possible with Lonza’s New PyroCell Monocyte Activation Test - Human Serum System

• The human serum-based system shows reduced interferences when testing for pyrogenicity in more complex drug products, such as in blood-derived therapeutics

By replacing fetal bovine serum, the new PyroCell^® MAT HS System increases sustainability by reducing the need for experimental animals and animal-derived components in pyrogen testing. Pharmaceutical manufacturers globally can now rely on Lonza for a range of high-quality, sensitive and sustainable in vitro pyrogen tests.

Janet Yancey-Wrona, Head of Marketing for Testing, Lonza BioScience, commented:"The pharmaceutical industry is looking to future-proof its quality control testing programs by reducing the use of experimental animals while employing robust tests suitable for use with the diversity of emerging biologics products. To support the unique needs of these new modalities and facilitate this shift, we are leveraging our collaboration with Sanquin Reagents to add the PyroCell MAT HS System to our testing portfolio. With our expanded offering of sustainable tests, customers can select the best in vitro pyrogen and endotoxin tests for their specific needs."

For more information, please visit www.lonza.com/mat